BioPharmSignal logoBioPharmSignal

Biotech News

RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3

RxSight (RXST)RxSightEarnings

ALISO VIEJO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on Tuesday, November 3, 2026. The company’s management will discuss the results during a conference call

Related news

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

OMOutset Medical2026-10-21 20:05 EST

Outset Medical to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

STXSStereotaxis2026-10-20 11:40 EST

Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026

IRTCiRhythm2026-10-15 20:05 EST

iRhythm Holdings to Report Third Quarter 2026 Financial Results on November 5, 2026

ADPTAdaptive Biotechnologies2026-10-14 20:05 EST

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

PRCTPROCEPT BioRobotics2026-10-12 20:05 EST

PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026

PLSEPulse Biosciences2026-10-22 20:05 EST

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

TCMDTactile Systems Technology, Inc.2026-10-19 20:05 EST

Tactile Medical to Release Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026

HYPRHyperfine2026-10-08 11:30 EST

Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026

View all latest news

RxSight

Adjustable Cataract Lenses RxSight is an ophthalmic medical-device company focused on customized vision after cataract surgery. Light Adjustable Lens System The system combines an implantable Light Adjustable Lens with a Light Delivery Device. After surgery, physicians use ultraviolet light treatments to modify the lens and refine the...

Recent company news

RXSTRxSight2026-10-20 20:05 EST

RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3

RXSTRxSight2026-10-19 13:00 EST

RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation

RXSTRxSight2026-08-26 20:15 EST

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

RXSTRxSight2026-08-05 20:05 EST

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

RXSTRxSight2026-07-26 20:00 EST

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Stock data

Close
4.90 USD
Market cap
204.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States